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ABSTRACT 
 
Cationic peptides proved fundamental importance as pharmaceutical agents and/or drug-
carrier moieties functioning in cellular processes. The comparison of the in vitro activity of 
these peptides is an experimental challenge and a combination of different methods, such as 
cytotoxicity, internalisation rate, haemolytic and antibacterial effect, is necessary. At the same 
time several issues need to be addressed as the assay conditions have a great influence on the 
measured biological effects and the experimental setup need to be optimised. Therefore, 
critical comparison of results from different assays using representative examples of cell 
penetrating and antimicrobial peptides was evaluated and optimal test conditions were 
suggested. Our main goal was to identify carrier peptides for drug delivery systems of 
antimicrobial drug candidates. Based on the results of internalisation, haemolytic, cytotoxic 
and antibacterial activity assays, a classification of cationic peptides is advocated. We found 
eight promising carrier peptides with good penetration ability of which Penetratin, Tat, 
Buforin and Dhvar4 peptides showed low adverse haemolytic effect. Penetratin, Transportan, 
Dhvar4 and the hybrid CM15 peptide had the most potent antibacterial activity on 
Streptococcus pneumoniae (MIC lower than 1.2 M) and Transportan was effective against 
Mycobacterium tuberculosis as well. The most selective peptide was the Penetratin, where the 
effective antimicrobial concentration on pneumococcus was more than 250-times lower than 
the HC50 value. Therefore, these peptides and their analogues will be further investigated as 
drug delivery systems for antimicrobial agents. 
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1. INTRODUCTION 
 
In the design and development of new antimicrobial drug candidates, delivery to target site is 
one of the major consideration. However, several libraries of synthetic compounds providing 
activity against a vast spectrum of pathogens have been discovered so far, the general inability 
to penetrate the target cells seems to be the main obstacles, especially in the case of diseases 
that are caused by intracellular bacteria (Brown and Wright 2016). 
 
The cellular uptake rate and the bioavailability of drug compounds can be enhanced by 
covalent attachment to appropriate targeting or carrier peptides. Cationic oligopeptides, 
including cell penetrating peptides (CPP) and certain antimicrobial peptides (AMP) have the 
ability to cross the lipid membrane and to access intracellular targets. However, a number of 
cationic oligopeptides entered clinical trials (Marr et al. 2006; Yeung et al. 2011) lack of cell 
specificity and extensive cytotoxicity remains a major drawback for further development. To 
improve the therapeutic effect of these peptides, intracellular trafficking and antimicrobial 
activity with low cytotoxicity toward human host cells is needed. For the calculation of the in 
vitro selectivity the haemolytic activity toward human red blood cells (RBC) is often used for 
the comparison to the antimicrobial activity (Chen et al. 2005). 
 
1.1. Experimental Conditions of In Vitro Assays  
To determine the in vitro selectivity of membrane active cationic peptides many types of 
biological assays are described in the literature. Previous studies have warned that the absence 
of haemolysis or high HC50 values in certain media (i.e. PBS) can give untrue results, when 
the selectivity index is calculated (Saberwal and Nagaraj 1994). Even in the case of the bee 
venom Melittin, haemolytic activity can be inhibited if the phosphate concentration is raised 
(Helmerhorst et al. 1999; Portlock et al. 1990). In general, the membrane activity of many 
cationic peptides is strongly dependent on the ionic strength and salt content of the used 
media (Helmerhorst et al. 1999; Herbel and Wink 2016). Raghuraman and colleagues studied 
the effect of ionic strength on the dynamics and aggregation behaviour of Melittin and they showed, 
that the peptide undergoes a structural transition from a random coil monomer to an α-helical tetramer 
at high ionic strength (Raghuraman and Chattopadhyay 2006; Raghuraman et al. 2006).  
 
The most significant differences in the test conditions can be found in the haemolytic assays 
of peptides. Important variants are as follows:  (i) concentration of RBC (0.5% v/v (Hollmann 
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et al. 2016), 1% (Kobayashi et al. 2000), 2% (Yang et al. 2013), 4% (Lee and Lee 2008; Song 
et al. 2005), 20% (Chongsiriwatana et al. 2008), 2 × 106 cells/mL (Li et al. 2005) or 2.5 × 108 
cells/mL (Dathe et al. 2001; Dathe et al. 1996), 1.2 × 109 cells/mL (Zeitler et al. 2013) etc.); 
(ii) incubation media (PBS (Chongsiriwatana et al. 2008; Dennison and Phoenix 2014; 
Hollmann et al. 2016; Lee and Lee 2008; Song et al. 2005), Tris (Dathe et al. 2001; Dathe et 
al. 1996; Zeitler et al. 2013), RPMI-1640 or HEPES buffer (Li et al. 2005), 0.9% NaCl or 
normal saline (Wu et al. 2014), etc.); (iii) incubation time (30 min (Hollmann et al. 2016; Wu 
et al. 2014), 1 hour (Chongsiriwatana et al. 2008; Dennison and Phoenix 2014; Yang et al. 
2013), 4 hrs (Li et al. 2005) or 18-24 hrs (Mojsoska et al. 2015)); (iii) used positive control 
(0.1% Triton-X (Dennison and Phoenix 2014; Lee and Lee 2008; Song et al. 2005), 1% 
Triton-X (Mojsoska et al. 2015), 10% Triton-X (Wu et al. 2014), distilled water (Hollmann et 
al. 2016; Yang et al. 2013), 2 % SDS (Zeitler et al. 2013), 0.05% saponin (Davanco et al. 
2014). There are differences even in the used wavelength at which the optical density of 
released haemoglobin is determined (λ=350 nm (Chongsiriwatana et al. 2008), 405-415 nm 
(Kaushik et al. 2012; Lee and Lee 2008; Song et al. 2005; Zeitler et al. 2013) , 540-550 nm 
(Davanco et al. 2014; Hollmann et al. 2016; Mojsoska et al. 2015; Yang et al. 2013) or 570 
nm (Dennison and Phoenix 2014; Wu et al. 2014)). 
 
Because of the different test conditions, it is questionable whether the results of the 
haemolytic assays can be properly compared to the antimicrobial activity and/or cytotoxicity 
that are usually performed in lower ionic strength media or broths (RPMI, HEPES, DMEM, 
Bouillon, etc.). Therefore we have investigated in the comparative analysis of haemolytic 
activity, cytotoxicity, cellular uptake and antimicrobial activity of cationic oligopeptides with 
the aim to clarify the role of experimental conditions such as the cell type, concentration of 
cells, used media, incubation time, anticoagulant and counter-ion, etc.  
 
1.2. Peptide Selection 
In this project, well studied cationic oligopeptides which can be considered as representative 
CPPs and AMPs, were chosen for critical analysis. Our goal was to identify peptides as 
promising antibacterial drug carriers with potent penetrating ability, antibacterial effect and 
suitable selectivity. Criteria of the peptide selection were the following: size (lower than 25 
amino acids); cationic character; synthetic considerations, such as bearing suitable 
conjugation site; literature data on membrane activity (e.g. cell penetration and/or 
antibacterial effect). 
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However, in many cases, the exact mechanism of bacterial killing of AMPs is not known, 
these evolutionarily conserved peptides can permeabilize the phospholipid membrane and 
provoke a broad spectrum of antimicrobial activity against bacteria, viruses, and fungi (Reddy 
et al. 2004; Yeaman and Yount 2003). Many antimicrobial peptides were isolated from 
amphibians, such as Magainin (Zasloff 1987) and Buforin (Park et al. 1996). Granulysin, a 9 
kDa protein found in granules of cytotoxic T lymphocytes and natural killer cells, lyses a 
variety of tumour and bacterial cells in vitro, and directly kill Mycobacterium tuberculosis 
(Stenger et al. 1998). GranF2, a 23-mer peptide synthetic derivative, represents a helix-loop-
helix region, which is postulated to be the membrane-docking part of Granulysin protein 
(Andreu et al. 1999). Histatins are salivary histidine-rich cationic peptides found in human 
parotid secretion. Synthetic derivatives, including Dhvar4, were studied on the ability to adopt 
helical conformation which is considered to be the key feature to act as membrane-active 
antimicrobial peptides (Helmerhorst et al. 1997). Crot(1-9,38-42) peptide is representing the 
N- and C-terminus of Crotamine, a toxin found in the venom of rattlesnake (Andreu et al. 
1992). Recently, chimera peptides were developed to improve the biological activity: CM15 
is a linear, hybrid AMP composed of Cecropin A (1-7) and Melittin (2-9) (Radis-Baptista et 
al. 2008). The major toxin found in bee venom is Melittin, a linear 26-residue peptide, which 
displays strong lytic activity against bacteria and human cells (Habermann 1972), and it is 
often used as a positive control in haemolytic assays. 
 
Cell penetrating peptides could have a great pharmaceutical potential as in vitro and in vivo 
delivery vectors for a wide range of bioactive cargos. CPPs are of different sizes, amino acid 
sequences, and charges but all published CPPs have the ability to translocate the plasma 
membrane and facilitate the delivery to the cytoplasm (El-Andaloussi et al. 2005; Hudecz et 
al. 2005; Morris et al. 2008; Vives et al. 2008). During the last two decades several CPPs 
were described. Tat (transactivator of transcription) and Penetratin, the two most studied 
CPPs, were derived from the sequence of HIV transactivator protein (Green and Loewenstein 
1988) and the third helix of the homeodomain of Drosophila Antennapedia protein (Derossi et 
al. 1994). Transportan is a hybrid peptide, constructed from a 6-residue sequence of the 
neuropeptide Galanin (GWTLNSAGYLLGPHAVGNHRSFSDKNGLTS) with a peptide 
toxin from wasp venom (mastoparan, INLKALAALAKKIL) connected via a lysine (Langel 
et al. 1996).  
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Tuftsin is a receptor binding peptide produced by the enzymatic cleavage of the Fc-domain of 
the heavy chain of immunoglobulin G. Based on the canine tuftsin sequence, [TKPKG]4 
(OT20) peptide was developed in our laboratory (Bai et al. 2008; Horvati et al. 2012; Mezo et 
al. 2004). OT20 peptide, a tetramer derivative of tuftsin, represents comparable chain length 
(20-mer), net charge (9+) and hydrophilicity therefore it was used as negative control in this 
study.  
 
2. MATERIALS AND METHODS 
 
Materials 
N,N’-diisopropylcarbodiimide (DIC), triisopropylsilane (TIS) and Amberlit IRA-400 anion-
exchange resin were purchased from Fluka. The amino acid derivatives were obtained from 
Reanal or from IRIS Biotech. 1-hydroxybenzotriazole (HOBt) and trifluoroacetic acid (TFA) 
was also from IRIS Biotech. Fmoc-Rink Amide MBHA resin was purchased from 
NovaBiochem. Acetonitrile and dimethyl sulfoxide (DMSO) were from Merck. N,N-
dimethylformamide (DMF) and dichloromethane (DCM) were from Reanal. 5(6)-
carboxyfluorescein (Cf) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) were obtained from 
Sigma-Aldrich. 
 
For the in vitro assays RPMI-1640 medium, Dulbecco's Modified Eagle's Medium (DMEM), 
fetal calf serum (FCS), nonessential amino acids, 3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT), sodium dodecyl sulfate (SDS), Löwenstein-Jensen medium base 
were obtained from Sigma-Aldrich. Sula medium, PBS buffer (10 mM sodium phosphate in 
150 mM NaCl, pH 7.4), Tris buffer (0.1 M tris(hydroxymethyl)aminomethane, pH 7.4, 
adjusted with HCl), and HPMI buffer (9 mM glucose, 10 mM NaHCO3, 119 mM NaCl, 9 mM 
HEPES, 5 mM KCl, 0.85 mM MgCl2, 0.053 mM CaCl2, 5 mM Na2HPO4 × 2H2O, pH 7.4) 
were prepared in our laboratory using components obtained from Sigma-Aldrich. 0.9% NaCl 
was a Fresenius infusion solution. 
 
2.1. Peptide Synthesis and Purification 
Peptides were produced on 100 mg Fmoc-Rink Amide MBHA (capacity = 0.67 mmol/g) resin 
in an automated peptide synthesizer (Syro-I, Biotage) using standard Fmoc/tBu strategy with 
DIC/HOBt coupling reagents. Peptides were cleaved from the resin with TFA/H2O/TIS (9.5 : 
2.5 : 2.5 v/v) mixture (2 hrs, RT). After filtration the compounds were precipitated in cold 
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diethyl ether, centrifuged (4000 rpm, 5 min) and freeze-dried from water. Crude products 
were purified by RP-HPLC on a semipreparative C-18 Phenomenex Jupiter column (250×10 
mm) using gradient elution, consisted of 0.1% TFA in water (eluent A) and 0.1% TFA in 
acetonitrile/water = 80/20 (v/v) (eluent B).  
 
For the cellular uptake studies N-terminus of the peptides were labelled with 5(6)-
carboxyfluorescein (Cf) using DIC/HOBt coupling method. Cleavage, work-up and 
purification of Cf-peptides were performed in the same way as mentioned above.  
 
2.2. Peptide Characterization 
Purified peptides were analysed by RP-HPLC on an analytical C-18 Eurospher-100 (5 µm, 
250×4 mm) column using gradient elution with the above mentioned eluent A and B (flow 
rate was 1 mL/min, UV detection at λ=220 nm).  
 
Molecular mass of peptides was determined by using a Bruker Esquire 3000+ ESI mass 
spectrometer.  Peptide samples were dissolved in a mixture of acetonitrile/water = 1/1 (v/v) 
containing 0.1% acetic acid and introduced by a syringe pump with a flow rate of 10 L/min. 
 
2.2.1. Determination of Peptide Content by Amino Acid Analysis  
The peptide content was determined by amino acid analysis using a Sykam Amino Acid 
S433H analyser equipped with an ion-exchange separation column and postcolumn 
derivatization. Prior to analysis, samples were hydrolysed with 6 M HCl in sealed and 
evacuated tubes at 110°C for 24 h. For post-column derivatization the ninhydrin-method was 
used. 
 
2.2.2. Counter Ion Replacement and the Determination of Fluorine Content 
Acetate-exchange of the purified peptides was performed using Amberlit IRA-400 (20-50 
mesh, Cl- form) anion-exchange resin. First the resin was washed with water, three times with 
0.2 M NaOH, washed with water, and treated with 20 v/v% acetic acid. After washing with 
water, 2 g resin was mixed with the peptide solution (26.5 mg / 4 ml of water). The peptide-
resin suspension was stirred for 1 h, then filtered and washed with 20 v/v% acetic acid and 
water. After freeze-drying, peptides were analysed by analytical RP-HPLC, ESI MS and 
amino acid analysis. To calculate the anion-exchange rate, the Fluorine content of the peptides 
was determined by using modified Schöniger method (Rogers and Yasuda 1959). The 
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exchange rate was calculated by dividing the percentage of the Fluorine content of acetate-
exchanged peptide by the percentage of the Fluorine content of the original peptide.  
 
2.2.3. Circular dichroism (CD) spectroscopic measurements and secondary structure 
estimation 
 
Peptide samples were dissolved in deionized water and in 10 mM, pH 7.3 potassium 
phosphate buffer (0.05 M Na2SO4). Far-UV CD curves were acquired on a JASCO J-715 
spectropolarimeter at 25  0.2 C in a 0.1 cm path-length rectangular quartz cuvette (Hellma, 
USA). Temperature control was provided by a Peltier thermostat. The CD data were 
monitored in continuous scanning mode between 185 and 260 nm at a rate of 50 nm/min, with 
a step size of 0.1 nm, response time of 2 sec, three accumulations, 2 nm bandwidth. The CD 
curves were corrected by spectral contribution of blank water or buffer solution. 
CD spectra were plotted in mean residue molar CD units (/ residue) calculated by the 
following equation: 
 = / (32982cl) 
where  is the measured ellipticity as a function of wavelength (nm), c is the molar 
concentration of the peptide, and l is the optical path length (cm).  
 
The secondary structure content of CM15 was estimated from the CD spectra using the MS 
Excel version of the PEPFIT program developed originally by Reed and Reed (Amon et al. 
2008; Reed and Reed 1997). It calculates the percentage of secondary contents by fitting 
experimental data to reference secondary structure spectra. The best fit is deﬁned by the R2 
value, where an R2 = 1 corresponds to a perfect fit. Before secondary structure analysis, the 
CD spectra were smoothed with a convolution width of 17 using the Means-Movement 
method (JASCO Spectra Analysis software, version 1.53.00). 
 
2.3. Haemolytic Activity Assay  
Peripheral blood from healthy volunteers was collected in vacuum tubes containing heparin 
(Li-heparin LH, VenoSafe) as anticoagulant. Tubes were centrifuged (1000 rpm, 5 min) and 
the pellet was washed 3 times with RPMI-1640 (culturing media without phenol red). To the 
pellet RPMI media was added to yield a final 4, 1, 0.25 or 0.0625 v/v% RBC suspension. 
Peptides were dissolved in the same media and three-fold serial dilution series were prepared 
(final concentration: 0.1 – 200 μM). RBC suspension (100 L/well) were placed into a 96-
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well cell culture plate and mixed with 100 L peptide solution. The plates were incubated for 
4 hrs at 37°C. After centrifugation (1500 rpm, 5 min), 100 L of the supernatant was 
transferred to a flat-bottom microtiter plate and absorbance was measured at 414 nm using an 
ELISA plate reader (iEMS Reader, Labsystems). The percentage haemolysis was compared to 
0.1 % Triton-X treated RBC and the concentration of peptide at which 50% haemolysis (HC50 
value) was determined.  
 
To study the time dependence of haemolysis, RBCs were incubated for 30 min or 4 hrs or 24 
hrs with CM15 peptide solution at 37°C using the same conditions as described above. To 
compare the effect of different anticoagulants on the haemolysis evoked by CM15 peptide, 
three types of vacuum tubes were used: heparin (Li-heparin LH, VenoSafe), EDTA (K3-
EDTA, VenoSafe), citrate (Na3-citrate 9NC, VenoSafe). The influence of different buffers 
was tested using either PBS, TRIS buffers, Bouillon broth, DMEM, RPMI (without phenol 
red) media or Fresenius 0.9% NaCl infusion solution. Always the same media was used for 
washing, culturing the erythrocytes and for dissolving the peptide samples. 
 
2.4. Cell Culturing, Cytotoxicity Assay and Cell Morphology 
Peripheral blood mononuclear cells (PBMC) were prepared from peripheral blood of healthy 
volunteers (purchased from Hungarian National Blood Transfusion Service, HNBTS) using 
Ficoll-Hypaque density gradient centrifugation method. PBMC were cultured in complete 
medium prepared from RPMI-1640 supplemented with 10% FCS, 2 mM L-glutamine and 160 
µg/mL gentamycin at 37°C in 5% CO2 atmosphere. Twenty-four hours prior to treatment, 
PBMC cells were plated into a 96-well round bottom plate (250.000 cell/100 L complete 
medium).  
 
MonoMac6 human monocytic cell line (DSMZ no.: ACC 124) and HepG2 human 
hepatocellular liver carcinoma cell line (ATCC HB-8065) were maintained under conditions 
described above. For cytotoxicity assay, cells were distributed on a 96-well flat bottom tissue 
culture plate (5000 cell/100 L complete RPMI-1640 medium). 
SH-SY5Y human neuroblastoma cell line (ATCC CRL-2266) was cultured in DMEM 
medium containing 10% FCS, 2 mM L-glutamine, 160 µg/mL gentamycin, 1 mM pyruvate 
and 1% nonessential amino acids. SH-SY5Y cells (10.000 cell/100 L complete DMEM 
medium) were plated into a 96-well flat bottom tissue culture plate.  
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Prior to treatment, cells were washed with serum-free RPMI-1640 (PBMC, MonoMac6, 
HepG2) or DMEM (SH-SY5Y) medium. Peptides to be tested were dissolved in serum-free 
medium and added to the cells to achieve 0.15 M – 300 M final concentration. Cells were 
incubated with the peptides for 4 hrs, then the cell viability was tested using MTT assay (Liu 
et al. 1997; Mosmann 1983; Slater et al. 1963). Briefly, 45 μL MTT solutions were added to 
each well (2 mg/ml, solved in serum-free medium). Following 4 hrs of incubation, plates were 
centrifuged at 2000 rpm for 5 minutes, and the supernatant was carefully aspirated with a G30 
needle. The precipitated purple crystals were dissolved in 100 μL DMSO, and after 10 
minutes agitation, the absorbance was determined at  = 540 nm and 620 nm using ELISA 
plate reader (iEMS Reader, Labsystems). Cytotoxicity, expressed in percentage as the 
function of peptide concentration was represented graphically and IC50 values were 
determined.  
 
To visualize cell morphology after peptide treatment, microscopic images of MonoMac6 cells 
were captured. MonoMac6 cells were plated in a 96-well flat bottom tissue culture plate (5000 
cell/100 L RPMI-1640 medium without phenol red), then treated with the peptides for 4 hrs 
at 1, 10 and 100 M final concentration. Microscopic images of the adherent cells were 
captured using an Olympus CKX41 microscope. 
 
2.5. Cellular Uptake Studies by Flow Cytometry  
The measurement of cell penetration of the compounds was evaluated on MonoMac6 human 
monocytic cell line by using a BD LSR II flow cytometer (BD Biosciences, San Jose, CA, 
USA) with 488 nm (Coherent Sapphire, 22 mW) laser. Cells were harvested in the 
logarithmic phase of growth and plated on a 24-well tissue culture plate (105 cells/1 mL 
medium/well) 24 hours prior to the experiment. Cf-labelled peptides were dissolved in serum 
free RPMI medium and added to the cells at 20, 10 and 5 µM final concentrations. Cells were 
incubated with compounds for 2 hrs (37 °C, 5% CO2 atmosphere). After centrifugation (1000 
rpm, 5 min) and washing with RPMI medium, supernatant was removed and 100 μL 1 mM 
trypsin was added to the cells. After 5 min incubation at 37 oC 0.8 mL 10% FCS/HPMI 
medium was added than cells were washed and re-suspended in 0.5 mL HPMI. The cell 
viability was assessed using 10 µg/mL propidium iodide (PI) solution (for the gating strategy 
see Supporting Information FIGURE S1). The intracellular fluorescence intensity of the cells 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 11 
was measured on channel PE LP550 (emission at λ = 550 nm) and data were analysed with 
FACSDiva 5.0 software. All measurements were performed in triplicates.   Parallel with flow 
cytometry measurements microscopic image of the cells were captured with an Olympus 
CKX41 microscope. 
 
2.6. In Vitro Antibacterial Activity Assay 
In vitro antibacterial activity of the compounds was determined against Streptococcus 
pneumoniae (ATCC 49619) by serial dilution method in Bouillon medium, which was 
prepared in-house. Compounds were added to the medium as 10 μL DMSO solutions in 
duplicates (range of final concentrations was between 1.2 and 300 μM). Each tube was 
inoculated with 0.5 Mcfarland bacteria and the minimal Inhibitory concentration (MIC) was 
determined after incubation at 37 oC for 24 hrs. MIC was the lowest concentration of a 
compound at which no visible growth of the bacteria occurred.  
 
Antitubercular effect of the compounds was also tested on Mycobacterium tuberculosis H37Rv 
(ATCC 27294) in Sula semisynthetic medium (prepared in-house) (Sula 1963; Sula and 
Sundaresan 1963; Vinsova et al. 2006) using previously described method (Baranyai et al. 
2015; Horvati et al. 2015). Compounds were dissolved in DMSO and added to the medium at 
ten various concentrations (c = 0.5 – 500 μM). MIC value was determined after incubation at 
37 oC for 28 days. In order to confirm the growth inhibition colony forming unit (CFU) was 
determined by subculturing from the Sula medium onto drug-free Löwensten-Jensen solid 
medium. Samples were further incubated for 28 days. Experiments were repeated at least two 
times. 
 
Selectivity indices were calculated from the concentration value where 50% of human RBCs 
were lysed (HC50) by the peptides divided by the minimal inhibitory concentration (MIC) 
determined against Streptococcus pneumoniae. Both in vitro measurements were performed in 
Bouillon broth using 24 hrs incubation time. 
 
2.7. Statistical Analysis 
In vitro tests were performed in triplicates and the results were expressed as mean ± Std. 
deviation. For the evaluation of haemolysis and cytotoxicity and for the determination of 
HC50 and IC50 values of the peptides dose-response curves were plotted with non-linear 
regression analysis using GraphPad Prism 5.0 software. The effects of different experimental 
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conditions (incubation time, media, percentage of RBC, anticoagulant and counter ion) were 
analysed by one-way ANOVA test by using GraphPad Prism 5.0 software. If means were 
significantly different (P < 0.05), than ANOVA test was followed by a t-test (unpaired, two-
tailed, confidence intervals: 95%). 
 
3. RESULTS AND DISCUSSION 
 
Representative examples of cationic oligopeptides, listed in TABLE 1, were critically 
analysed and compared in well-defined in vitro assays. Our aim was to find good future 
peptide candidates for antimicrobial drug delivery. Cytotoxicity, haemolytic and antimicrobial 
activity of membrane-active peptides is often used to estimate their therapeutic applicability 
(Helmerhorst et al. 1999; Maher and McClean 2006). In this paper, we show that the 
calculated selectivity index is strongly dependent on the conditions (i.e. culturing media) of 
the in vitro assays. Therefore, systematic studies were performed to establish proper test 
conditions for accurate comparison. All 11 peptides were then tested on PBMC and 
MonoMac6 cells, against two bacterial strains (S. pneumoniae and M. tuberculosis) and on 
human erythrocytes in different incubation media. As positive control, Melittin was used 
which has strong lytic activity against microbes and human cells. OT20 was the negative 
control in this study. OT20 is a non membrane-active, receptor binding peptide, which 
represents comparable cationic character. 
 
TABLE 1. Origin and classification of cationic oligopeptides used in this study  
peptide classification origin ref. 
Tat(47-57) CPP HIV transactivator protein 
(Green and Loewenstein 
1988) 
Penetratin CPP Drosophila Antennapedia protein (Derossi et al. 1994) 
Transportan hybrid CPP 
constructed from Galanin and 
Mastoparan proteins 
(Langel et al. 1996) 
Magainin AMP peptide from Xenopus laevis skin (Zasloff 1987) 
Buforin II  
(5-21) 
AMP 
peptide from the stomach tissue of  Bufo 
bufo garagrizans 
(Park et al. 1996) 
GranF2 AMP peptide derived from Granulysin protein 
(Andreu et al. 1999; Stenger 
et al. 1998) 
Dhvar4 designed AMP human salivary Histatin derivative (Helmerhorst et al. 1997) 
Crot(1-9,38- designed AMP Crotamine, a toxin of Crotalus durissus (Andreu et al. 1992) 
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42) terrificus 
CM15 hybrid AMP from Cecropin A and Melittin sequences (Radis-Baptista et al. 2008) 
Melittin 
positive control 
(strong lytic 
activity) 
venom of Apis mellifera (Habermann 1972) 
OT20 
negative control 
peptide 
tetramer derivative of tuftsin sequence (Bai et al. 2008) 
 
3.1. Synthesis and Characteristics of Cationic Peptides 
Cationic peptides, listed in TABLE 2, were synthesized, purified and carefully characterized 
by analytical RP-HPLC, ESI MS and amino acid analysis.  
 
Throughout experimental design it is important to note that the peptide content of a 
lyophilised material can vary according to the sequence and the used synthetic procedures. 
Generally, the content of residual salt and water, which are the main impurities in a 
lyophilized peptide, can be up to 40-50%, especially in the case of high number of positively 
charged amino acids in the sequence. For more reliable comparison, precise determination of 
peptide content was evaluated by amino acid analysis. We found that the higher the average 
hydrophilicity (H) was, the lower peptide content was measured. The average peptide content 
was 50%, the lowest value was 41% for Tat(47-57) peptide (9+ charge in 11 amino acids), the 
highest was 58% for Magainin (4+ charge in 23 amino acids) (TABLE 2).  
 
TABLE 2. Analytical characteristics of  cationic peptides 
peptide sequence 
Z a 
 
Mav
 b
 
calcd / found 
Rt c 
(min) 
H d 
 
peptide 
content e 
% 
Tat(47-57) YGRKKRRQRRR 9+ 1558.9/1559.2 15.5 +2.0 41 
Penetratin RQIKIWFQNRRMKWKK 8+ 2245.7/2245.6 25.9 +0.5 49 
Transportan AGYLLGKINLKALAALAKKIL 5+ 2181.8/2181.9 29.1* -0.3 56 
Magainin GIGKFLHSAKKFGKAFVGEIMNS 4+ 2465.9/2466.0 33.0 -0.1 58 
Buforin II (5-21) RAGLQFPVGRVHRLLRK 6+ 2002.4/2002.5 26.8 +0.2 52 
GranF2 VCRTGRSRWRDVCRNFMRRYQSR 8+ 2988.5/2988.7 27.7 +0.6 45 
Dhvar4 KRLFKKLLFSLRKY 7+ 1839.4/1839.6 29.6 +0.3 48 
Crot(1-9,38-42) YKQCHKKGGKKGSG 6+ 1504.8/1504.9 11.3 +0.8 48 
CM15 KWKLFKKIGAVLKVL 6+ 1770.3/1770.4 32.0 -0.1 52 
Melittin GIGAVLKVLTTGLPALISWIKRKRQQ 6+ 2846.5/2846.6 39.6 -0.2 57 
OT20 TKPKGTKPKGTKPKGTKPKG 9+ 2063.5/2063.5 14.8 +1.1 49 
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C-terminus of the peptides was amidated. 
 a Z: net charge at neutral pH. Calculated by the number of (K+R)-(E+D). Positive charge at the N-terminus 
increases Z by 1 unit.  
b
 Measured average molecular mass by Bruker Esquire 3000+ ESI-MS.  
c
Analytical RP-HPLC, gradient: 5% B, 5 min; 5-60% B, 35 min. * gradient: 10% B, 5 min; 10-80% B, 35 min. 
d H: hydrophilicity is calculated from the average of hydrophilicity values of each amino acids (Hopp and Woods 
1981). 
e Peptide content was determined by amino acid analysis using freeze-dried final product.  
 
3.1.1. Counter-Ion Replacement 
After standard solid phase synthesis and purification, cationic peptides are often isolated as 
trifluoroacetate salts (Roux et al. 2008; Vemuri 2005). In the case of lysine and arginine rich 
peptide, the high amount of TFA can modify the biological and physicochemical properties 
(i.e. by modifying the conformation of the peptide, acidifying the media, and lowering the 
peptide content of the lyophilized powder). The removal of excess TFA and change 
trifluoroacetate counter-ion into acetate, which is less acidic, less toxic and has lower 
molecular mass, was performed using Amberlit IRA-400 anion-exchange resin. Anion-
exchange rate was monitored by elemental analysis. The Fluorine content of the peptide after 
acetate-exchange was decreased dramatically and the calculated exchange rate was up to 80% 
(F% = 13.42 (unchanged peptide); 2.88 (acetate-exchanged)). 
 
3.1.2. Circular Dichroism Spectroscopic Investigation of the Secondary Structure of 
CM15 Peptide 
Far-UV CD spectra of peptides represent the summation of signals from the optically active 
n-* and -* transitions of the amide bonds (Toniolo et al. 2012). -Helical structures 
display a negative n-* CD band at ~220 nm and two, higher intensity negative-positive peaks 
at ~207 and ~190 nm, respectively. This couplet is attributable to chiral exciton interaction of 
the helically arranged amide chromophores. The -sheet CD pattern consists of a negative n-
* band near 217 nm and two -* exciton components below 200 nm. Unordered peptides 
and proteins show a strong negative peak centered in the 195-200 nm region and substantially 
weaker, positive or negative signals above 215 nm. Taking these into consideration, the CD 
curve of CM15 measured in water (pH ~ 6) is characteristic to the dominant contribution of 
the unordered or random coil structure (FIGURE 1) (Pistolesi et al. 2007). In full concordance 
with this, quantitative analysis of the CD data yielded 62% random coil and 26% β-sheet with 
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no α-helical content. Interestingly, a small fraction of type III β-turn (Reed and Reed 1997) 
was also required to achieve the best fit between the experimental and calculated data 
(FIGURE 1). In relation to water, the negative CD band is red shifted above 200 nm in buffer 
solution together with the development of a prominent shoulder above 215 nm. According to 
the secondary structure estimation, these spectral changes can be associated to a β-turn  α-
helix conformational conversion (FIGURE 1). These results suggest that the pH of the 
medium where CM15 acts, e.g., normal or acidic inflamed tissues, may provoke a slight, but 
significant modification of its secondary structure. 
 
FIGURE 1. Far-UV CD spectra of CM15 peptide. CM15 peptide (30 μM) was measured in 
deionized water (pH ~ 6, 0.05 M Na2SO4) and in 10 mM, pH 7.3 potassium phosphate buffer 
(0.05 M Na2SO4), panel A. Panel B represents the results of the curve-fitting procedure made by 
using the PEPFIT analysis program (α-H: α-helix; β-S: β-sheet; r-C: random coil; β-T: type III β-
turn). The inset shows the estimated secondary structure percentages of the peptide. 
 
3.2. Haemolytic Activity of Peptides: Effect of Experimental Conditions 
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Published methods to determine haemolytic activity of cationic peptides often use different 
test conditions that can strongly influence the results. Therefore the effect of time, incubation 
buffer, concentration of RBC, identity of anticoagulant and counter-ion on haemolytic activity 
of cationic peptides was investigated. To establish proper test conditions CM15 peptide was 
chosen because of its average characteristics (charge and size) and medium haemolytic 
activity. 
 
3.2.1 Incubation Time and Media 
First, the time dependence of haemolysis evoked by cationic peptides was studied. 
Erythrocytes were incubated for 30 min, 2 hrs, 4 hrs or 24 hrs with CM15 peptide. Half an 
hour was enough to reach the maximum haemolysis; no further haemoglobin release was 
detected (FIGURE 1 A, B). Comparing the means of the HC50 values no significant difference 
was observed (P = 0.4449). 
 
In contrast, the type of incubation media strongly influenced the haemolytic activity of CM15 
peptide. The resulted means of HC50 values showed significantly difference (P < 0.0001) in 
the one-way ANOVA test. In the measurement of haemolysis, isotonic conditions are required 
to prevent erythrocytes from spontaneous lysis. Most commonly PBS and TRIS buffers are 
used in haemolytic assays however, for antimicrobial and cytotoxic assays these are 
considered to be high salt buffers (Helmerhorst et al. 1999). RPMI, DMEM and other cell 
culturing media contain amino acids, vitamins, glucose as well as additional supplementary 
components to be optimal for cultivation of certain cell types and are formulated to have the 
final osmolality in the range of 290 to 310 mOs/kg. It was found that the haemolytic activity 
of CM15 peptide is significantly lower (P < 0.0001) in PBS (28.2 ± 1.22 μM) than in cell 
culturing DMEM media (DMEM: 6.70 ± 0.50 μM). Haemolysis in RPMI, DMEM and 
Bouillon broth were in the range of 6.70 to 15.32 μM (FIGURE 2 C, D). For other cationic 
peptides, same results were found namely lower HC50 values were measured in PBS and Tris 
buffers than cell culturing media and broths (data not shown). 
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FIGURE 2. Effect of incubation time (A, B) and media (C, D) on the haemolytic activity of 
CM15 peptide. Human erythrocytes were treated with CM15 peptide at various concentrations 
using different experimental conditions and the haemolysis was determined by reading the 
absorbance of the supernatant at =414 nm. Haemolysis of the erythrocytes reached the maximum 
after 30 min treatment and no further haemoglobin release was measured. The haemolytic activity 
of CM15 peptide is strongly dependent on the used incubation buffer: in PBS significantly lower 
HC50 value was measured than in low ionic strength media or broth. (One-way ANOVA test, 
means are significantly different, P < 0.0001). 
 
In published methods there are differences even in the used wavelength at which the 
absorbance of the supernatant is measured. Percentage of haemolysis is calculated by dividing 
the absorbance measured for the peptide by the absorbance measured for the positive control 
(both values are corrected with the background). Therefore, the resulted % haemolysis values 
are independent from the exact absorbance values. However, better results can be obtained if 
we measure at the maximum wavelength of the released haemoglobin. We found that the 
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highest values can be measured if we monitor the absorbance at 414 nm or 405 nm (TABLE 
3).  
 
TABLE 3. Absorbance of the released haemoglobin at different wavelength 
Wavelength Absorbance a ± Sd a 
340 nm 2.034 0.001 
405 nm 4.456 0.016 
414 nm 4.576 0.120 
450 nm 1.190 0.018 
492 nm 0.440 0.003 
540 nm 1.047 0.006 
Peptide treated erythrocytes were centrifuged and the supernatants were 
transferred to a flat-bottom microtiter plate. The absorbance was measured at 
various wavelengths using an ELISA plate reader.  
a Means and standard deviations of two measurements. 
   
3.2.2. Concentration of Red Blood Cells, Anticoagulant and Counter Ion 
The percentage or cell number of RBC used in haemolytic assays differs in a wide 
concentration range. Therefore, to clarify the effect of RBC content, haemolysis of CM15 
peptide was studied at 4%, 1%, 0.25% or 0.0625% RBC concentration. No difference was 
measured (P = 0.2862) for 4%, 1%, 0.25%, while at 0.0625% RBC concentration significantly 
lower HC50 value was measured (P = 0.0004) (FIGURE 3A, B) 
 
Although, published methods for analysis of haemolytic activity of cationic peptides 
mentioned different anticoagulant containing vacuum tubes for cupping, no systematic study 
was evaluated on the effect of anticoagulants. Therefore, most frequently used anticoagulant 
containing vacuum tubes were used to compare the effect of citrate, heparin and EDTA on the 
haemolytic activity of CM15 peptide. The results clearly showed that lysis of the red blood 
cells by CM15 cationic peptide was independent of the used anticoagulant (P = 0.1210) 
(FIGURE 3C). 
 
In the case of lysine and arginine rich peptides, the high amount of TFA could alter the 
biological activity. Therefore, excess TFA and trifluoroacetate counter-ion was removed and 
changed to acetate counter-ion and the haemolytic activity of trifluoroacetate and acetate 
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counter-ion containing CM15 peptide was assayed. No marked effect of counter-ion identity 
could be observed in case of CM15 peptide treated RBC (P = 0.4106) (FIGURE 3D).  
  
FIGURE 3. Effect of erythrocyte concentration (A, B), identity of anticoagulant (C) and 
counter-ion (D) on the haemolytic activity of CM15 peptide. Human RBCs were treated with 
CM15 peptide using different test conditions and the haemolysis was determined by reading the 
absorbance of the supernatant at = 414 nm. Haemoglobin release of 4%, 1%, 0.25% v/v RBCs 
evoked by the CM15 peptide showed no significant difference, while at 0.0625% RBC 
concentration significantly lower HC50 value was measured (A and B). No significant differences 
in the resulted HC50 values were detected after using three different anticoagulants (C). Counter-
ion replacement has no significant effect on the haemolytic activity of CM15 peptide. (One-way 
ANOVA test, *** means P < 0.0005). 
 
3.3. Cytotoxicity of Cationic Peptides 
Cytotoxicity of cationic peptides was studied on freshly prepared human PBMC in RPMI 
media (incubation time was 4 hrs) using MTT test. PBMC are isolated human cells which can 
be used to study general toxicity of a compound. The following order of cytotoxicity was 
found: (i) Melittin, Transportan, CM15 and Dhvar4 peptides have IC50 value lower than 50 
μM; (ii) modest cytotoxicity (50 – 300 μM) was measured for GranF2, Magainin and 
A B 
C D 
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Penetratin; (iii) Tat(47-57), Buforin II, Crot(1-9,38-42) and OT20 peptides were not cytotoxic 
up to 300 M (TABLE 4).  
 
When measuring the haemolytic activity of the peptides employing the same experimental 
conditions as for the cytotoxic assay (RPMI media, 4 hrs of incubation), almost the same 
order of activity was found, namely the highest HC50 values were measured for Melittin, 
Transportan, CM15, and Transportan. Dhvar4 and GranF2 peptides were found to be 
cytotoxic to PBMC cells but not for red blood cells (HC50 > 300 μM).  
 
TABLE 4. Cytotoxic, haemolytic  and antibacterial effect of cationic oligopeptides 
peptide IC50 a 
(M) 
HC50 b 
(M) 
MIC c 
(M) 
HC50 d 
(M) 
Selectivity 
index e 
MTB MIC f 
(M) 
Tat(47-57) >300 >300 300 >300 1 >300 
Penetratin 136±25.6 >300 1.2 >300 250 >300 
Transportan 8.49±1.39 38.0±3.79 1.2 25.2±3.29 21 80 
Magainin 132±23.8 >300 33 >300 9 >300 
Buforin II (5-21) >300 >300 >300 >300 1 >300 
GranF2 80.1±18.5 >300 100 269±7.11 3 >300 
Dhvar4 38.6±5.76 >300 3.7 >300 81 >300 
Crot(1-9,38-42) >300 >300 >300 >300 1 >300 
CM15 12.9±2.51 18.9±1.71 1.2 13.9±0.456 12 >300 
Melittin 0.941±0.237 0.339±0.0854 1.2 0.681±0.0542 0.6 >300 
OT20 >300 >300 >300 >300 1 >300 
a Mean IC50 ± standard deviation. Cytotoxicity of peptides on human PBMC measured in RPMI media (4 hrs 
incubation time).  
b Mean HC50 ± standard deviation. HC50 is a concentration at which 50% haemolysis of human RBCs occurs in 
RPMI (without phenol red) media (4 hrs incubation time).  
c Minimal inhibitory concentration on Streptococcus pneumoniae strain determined in Bouillon broth (24 hrs of 
incubation).  
d Mean HC50 ± standard deviation determined in Bouillon broth with 24 hrs of incubation. 
e Selectivity index was calculated from HC50/MIC (both measured in Bouillon broth).  
f Minimal inhibitory concentration on Mycobacterium tuberculosis H37Rv strain determined in Sula media.  
For samples, where MIC, IC50 or HC50 was higher than 300 M, a value of 300 M was assigned. 
 
To estimate the cell-type dependence of cationic peptides four different human cells and cell 
lines were used. HepG2 human hepatocytes and SH-SY5Y human neuroblastoma cells are 
frequently used as hepatotoxicity and neurotoxicity model. MonoMac6 human monocytic cell 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 21 
line is a macrophage model which is suitable to bear intracellular bacteria. Cells were treated 
with Transportan at various peptide concentrations and the cytotoxicity was determined by 
MTT assay. Mean IC50 values showed significant difference (P < 0.05) however, all IC50 
were in the same concentration range: 4.70±1.02 M (MonoMac6), 6.78±0.488 M (HepG2), 
8.28±0.573 M (SH-SY5Y), 9.81±0.473 M (PBMC) (FIGURE 4).  
 
 
FIGURE 4. Cell-type dependence in the cytotoxicity assay. Freshly isolated PBMC, 
MonoMac6 human monocytes, HepG2 human hepatocytes and SH-SY5Y human neuroblastoma 
cells were treated with the peptide for 4 hrs at various concentrations and the cytotoxicity was 
determined by MTT assay. Comparing the IC50 values in one-way ANOVA test, significant 
difference was calculated however, the resulted IC50 values were at the same concentration range 
(between 4.70 μM and 9.81 μM). 
 
 
MonoMac6, which are adherent cells, were chosen to visualize the changes in the cell 
morphology caused by cationic peptides (FIGURE 5). Microscopic images of the peptide 
treated cells were captured using an Olympus CKX41 microscope. After treatment with 
Buforin II (5-21), Crot(1-9,38-42) and OT20 peptides, intact MonoMac6 cells were observed. 
Melittin, Transportan, CM15, Dhvar4 and GranF2 peptides caused severe damage on the cell 
membrane and provoked dramatic changes in the cell morphology. Penetratin, Magainin and 
Tat(47-57) peptides effected the cell membrane integrity just at the highest (100 M) 
concentration. These microscopic observations are in accordance with the result of the MTT 
assay. 
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FIGURE 5. Microscopic images of cationic peptide treated MonoMac6 cells. Cells were 
incubated with the peptides for 4 hrs at 1, 10 and 100 M final concentration. Dramatic changes in 
the cell morphology were captured in the case of Melittin, Transportan, Dhvar4, CM15, and 
GranF2 peptides, which results are in accordance with the MTT assay.  
 
3.4. Internalisation of Cationic Peptides 
Cellular uptake of MonoMac6 human monocytic cells was measured by flow cytometry. For 
that purpose, peptides were labelled with 5(6)-carboxyfluorescein (Cf) and measured at 20, 10 
and 5 µM final concentrations (FIGURE 6). Based on the internalisation ability, three groups 
of peptides were created: (i) superior penetration was defined for peptides where the 
percentage of FITC positive cells was higher than 80% at 5 µM concentration – Penetratin, 
Transportan, Dhvar4 and Melittin; (ii) good penetration for peptides where the percentage of 
FITC positive cells was higher than 50% at 10 µM concentration – Tat, GranF2, CM15 and 
Buforin II; and (iii) modest penetration where the percentage of FITC positive cells was 
higher than 50% at 20 µM concentration – Crot(1-9,38-42), Magainin II and OT20. It is 
important to note, that peptides with superior penetration shows the highest cytotoxicity, 
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especially Melittin, Transportan and Dhvar4. However, Penetratin, Tat and Buforin II 
peptides bear good internalisation property but low cytotoxicity.  
    
FIGURE 6. Internalisation of cationic peptides. Cellular uptake of MonoMac6 cells were measured by flow 
cytometry using 5(6)-carboxyfluorescein (Cf)-labelled peptides at 5, 10 and 20 μM concentration. The 
penetration ability was ranked according to the resulted percentage of FITC positive cells. Superior penetration: 
Penetratin, Transportan, Dhvar4 and Melittin; good penetrations: Tat, GranF2, CM15 and Buforin II; modest 
penetration: Crot(1-9,38-42), Magainin II and OT20. 
 
3.5. Antibacterial Activity against S. pneumonia. 
Antimicrobial efficacy of cationic peptides was measured against Streptococcus pneumoniae, 
a Gram-positive bacterium which is one of the most significant human pathogen (TABLE 4). 
Buforin II, Crot(1-9,38-42), Tat and OT20 control peptide were not effective against S. 
pneumonia. Magainin and GranF2 showed modest activity; CM15 and Dhvar4 peptides had 
potent antibacterial activity (less than 4 M) just as Melittin. Interestingly, Penetratin and 
Transportan, which are classified as cell penetrating peptides, showed relevant antibacterial 
activity against Streptococcus pneumoniae. In the case of Penetratin, these findings are in 
accordance with a previous data, which suggested that the membrane induced –helical 
structure makes this peptide similar in activity to AMPs (Magzoub et al. 2002; Zhu and Shin 
2009).  
 
3.6. Transportan Is Effective against M. tuberculosis 
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Antitubercular effect of all peptides was tested also on M. tuberculosis H37Rv strain. M. 
tuberculosis, the causative agent of tuberculosis, can survive in the host phagocytes for years 
or even decades and it is estimated that more than one-third of the world’s population are 
infected with these pathogen (Lienhardt et al. 2012). Our results demonstrated that none of the 
peptides were effective against M. tuberculosis up to 300 μM concentration, except 
Transportan. The MIC of Transportan peptide was 80 M. No published data were found 
recently on the antitubercular effect of Transportan.  
 
3.7. In Vitro Selectivity of Cationic Peptides 
We found, that the haemolytic activity of the tested peptides is significantly lower in PBS 
than in RPMI or in Bouillon broth. Therefore, selectivity indices (given in TABLE 4) were 
calculated from the results of experiments using the same buffer and incubation time. Based 
on the comparison of antitubercular effect and haemolytic activity, most selective peptides 
(where the selectivity indices were higher than 20) were Penetratin, Dhvar4 and Transportan. 
Among these peptides, Penetratin showed the best selectivity, because the MIC value of 
Penetratin was 250 times lower than its HC50 value. Modest selectivity was found for 
Magainin II, GranF2 and CM15 peptides. Up to the highest concentration (300 M) no 
antibacterial and haemolytic activities were observed for Buforin II, Crot(1-9,38-42), Tat and 
OT20 peptides (TABLE 4). In the case of the positive control peptide Melittin, the MIC value 
was higher than the HC50 value.  
 
4. CONCLUSION 
 
Here we report the comparative analysis of cationic oligopeptides to identify potent 
antibacterial carriers for drug delivery. Peptide synthesis and purification was followed by 
accurate characterization of the product (molecular mass, retention time, peptide content). 
Haemolytic activity and cytotoxicity on isolated human blood cells and different cell lines 
have been systematically studied and compared to their penetrating ability and antibacterial 
activity against Streptococcus pneumoniae (pneumococcus) and Mycobacterium tuberculosis. 
We also clarified the role of the used media, incubation time, RBC concentration, type of 
anticoagulant and counter-ion on the haemolytic activity of the peptides. We found, that the 
lytic activity of cationic peptides strongly depends on the used incubation media, which 
observation is in accordance with the results of the circular dichroism measurement. 
Therefore, it is uncertain whether the results of haemolytic assays, that are conducted in high 
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salt buffers such as Tris od PBS, can be compared properly with the results of antibacterial 
assays, that are conducted in low ionic strength buffers or broths. Because of this observation, 
the same incubation media was applied both for the antibacterial assay and the haemolytic 
assay. We also found that the haemolytic activity of cationic peptides was almost independent 
from the other conditions like incubation time and type of anticoagulant. For a proper 
haemolytic assay, performed on human erythrocytes, at least 0.25% v/v RBC concentration is 
required, which is equal to approximately 1 - 1.25 × 107 cells / mL (counting with the 
reference range of RBC of a male or female blood). When measuring the cytotoxicity of 
cationic peptides on different human cells and cell lines, almost the same order of activity was 
found than in the haemolytic assay.   
 
As a summary of the performed assays we can conclude the following: (i) eight peptides 
showed superior or good penetration of which Tat, Penetratin, Dhvar4 and Buforin peptides 
have low haemolytic activity. Therefore, these peptides can be considered as good carriers for 
different drug molecules without causing severe damage on human cells. (ii) Transportan was 
found to be effective against M. tuberculosis H37Rv bacteria. However, Transportan was 
cytotoxic at this concentration range. (iii) Dhvar4 peptide showed superior antibacterial effect 
and penetration ability although, this peptide was cytotoxic to human PBMC but not to human 
erythrocytes. (iv) Penetratin was identified as promising antibacterial drug carrier with 
potent antibacterial effect (MIC lower than 1.2 M on pneumococcus) and superior 
penetration ability with low in vitro toxicity on human cells. Conjugation of an antibacterial 
drug to an antibacterial peptide is proposed to intensify the efficacy by multiple mode of 
action: including bacterial cell lysis, inhibiting bacterial enzymes, interacting directly with the 
cytoplasmic membrane and inhibiting intracellular targets. In addition, the consequence of the 
multiple mechanism of action is the low potential to induce microbial resistance. Therefore, 
Penetratin and its analogues with remarkable antibacterial activity and high selectivity will be 
further investigated as drug delivery systems for antibacterial agents.  
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